NASDAQ · Biotechnology

ABUS (ABUS) Stock

$4.41 +0.00% NASDAQ: ABUS Healthcare

Valuation

MetricValue
Price$4.41
Market Cap$871.14M
P/E Ratio-25.41
P/B Ratio11.04
P/S Ratio4.30
EPS (TTM)$-0.17
52-Week High$5.31
52-Week Low$3.04
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-44.16%
ROA-35.79%
ROCE-35.06%
Gross Margin-192.86%
Operating Margin-192.86%
Net Margin83.95%
Debt/Equity0.05
Current Ratio15.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$11.0M$39.0M$18.0M$6.0M$14.0M
Operating Profit$-74.0M$-65.0M$-78.0M$-76.0M$-27.0M
Net Profit$-76.0M$-69.0M$-73.0M$-70.0M$-34.0M
EPS$-0.73$-0.46$-0.44$-0.38$-0.17
Op Margin-669.1%-167.8%-430.5%-1236.7%-192.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$204.0M$195.0M$144.0M$132.0M$95.0M
Total Liabilities$35.0M$59.0M$38.0M$34.0M$18.0M
Cash$109.0M$31.0M$26.0M$36.0M$18.0M
Borrowings$19.0M$13.0M$9.0M$1.0M$4.0M

Latest News

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? Stocktwits · Jul 16, 2026 Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents MT Newswires · Jul 16, 2026 Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders GlobeNewswire · Jul 16, 2026 Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks Simply Wall St. · Jul 9, 2026 ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week Stocktwits · Jul 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-68.0M$-35.0M$-86.0M$-65.0M$-40.0M
Investing Cash Flow$-13.0M$-75.0M$50.0M$23.0M$16.0M
Financing Cash Flow$15.0M$11.0M$1.0M$8.0M$0
Net Cash Flow$57.0M$-79.0M$-4.0M$10.0M$-18.0M
Free Cash Flow$-68.0M$-36.0M$-87.0M$-65.0M$-40.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-4.17%
Quick Ratio54.26
Interest Coverage—
Return 1Y38.39%
Return 3Y106.94%
Return 5Y73.96%

Ownership

Insiders Held20.46%
Institutions Held71.92%
Institutions Float Held90.42%
Institutional HolderSharesReport Date
Morgan Stanley25,891,4802026-03-31
Two Seas Capital Lp18,557,5432026-03-31
Whitefort Capital Management, LP14,930,8852026-03-31
Blackrock Inc.12,966,9462026-03-31
Vanguard Capital Management LLC6,688,9112026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BCAX $27.81 +2.92% -7.37 $1.52B 0.00%
EYPT $12.41 +1.80% -4.34 $1.04B 0.00%
GHRS $29.10 -0.06% -10.34 $2.00B 0.00%
KURA $9.57 +3.13% -2.90 $849.57M 0.00%
NBTXNanobiotix S.A. $40.18 +1.21% -68.71 $2.03B 0.00%

About ABUS

ABUS is led by CEO Lindsay Androski, employs 44 people, headquartered in US, publicly traded since 2007.

ABUS stock trades at $4.41 with a market capitalization of $871.14M. The stock is valued at a price-to-earnings (P/E) ratio of -25.41, price-to-book of 11.04, price-to-sales of 4.30. Over the past 52 weeks the stock has ranged between $3.04 and $5.31, and currently trades 16.9% below its 52-week high.

On profitability, ABUS generates a return on equity (ROE) of -44.16%, return on capital employed of -35.06%, an operating margin of -192.86%, a net profit margin of 83.95%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides